Breast cancer represents the most commonly detected form of cancer in women and stands as the primary contributor to cancer-related mortality among women on a global scale. This study was designed to evaluate the alterations in concentrations of some blood biomarkers implicated in the regulation of iron balance in Iraqi women with breast cancer and to explore the multifaceted role that these indicators play in the progression of this disease. The current investigation comprised a cohort of 55 females diagnosed with breast cancer, with a control group of 45 healthy participants. The levels of iron status markers that include hepcidin, ferritin, and ferroportin were estimated in the serum of breast cancer patients, as well as the values of some hematological parameters such as erythrocytes (RBCs), hemoglobin (Hb), hematocrit (HCT), leukocytes (WBCs), and thrombocytes (platelets). The results of the present study indicated that there were significant differences (p<0.05) in all indicators studied in the serum of breast cancer patients in comparison with the control group. Thus, these results may support the evidence about the potential role of these markers in breast cancer disease.